BIOMAT Database Logo BIOMAT Database Logo

Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. 1994

R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Department of Haematology, Hospital de la Princesa, Madrid, Spain.

Fifty patients with aplastic anemia (AA) were treated with BMT or immunosuppressive therapy (IST). Twenty-one patients underwent BMT using cyclophosphamide (CY) and 7 Gy total lymphoid irradiation (TLI) and cyclosporin A (CsA) plus methotrexate (MTX). Actuarial survival is 71% at 5.3 years with an incidence of graft failure of 0% and of acute GVHD of 38.9%. Univariate analysis of variables influencing survival showed a trend for a poorer outcome in patients who received > 30 transfusions prior to BMT and in male recipients from female donors. Twenty-nine patients > 40 years of age or without matched siblings received antithymocyte/antilymphocyte globulin (ATG/ALG). Response rate to the first course of treatment was 46.4%. Subsequent courses of IST rescued 33% of patients who relapsed or had not responded. Actuarial survival is 62% at 8.6 years. In our experience both treatment strategies have given encouraging results although overall morbidity is higher in the IST group because 25% of patients are therapy or transfusion-dependent. The role of irradiation in the conditioning regimen of BMT patients, recently challenged, is discussed.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.
August 2016, International journal of hematology,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial.
August 2003, International journal of hematology,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Immunosuppressive therapy versus bone marrow transplantation for children with aplastic anemia.
January 1989, Pediatrics,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
[Transfusion therapy in patients with severe aplastic anemia after bone marrow transplantation].
February 1985, Lijecnicki vjesnik,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Immunosuppressive therapy vs. bone marrow transplant for severe aplastic anemia.
January 1997, Journal of pediatric hematology/oncology,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia.
March 1998, Blood,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Magnetic resonance imaging of the bone marrow after bone marrow transplantation or immunosuppressive therapy in aplastic anemia.
December 2001, Journal of Korean medical science,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
A Rational Appraisal of Bone Marrow Transplantation and Immunosuppressive Therapy for Severe Aplastic Anemia.
May 1994, Cancer control : journal of the Moffitt Cancer Center,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Bone marrow transplantation in 65 patients with severe aplastic anemia.
January 1981, Bulletin du cancer,
R Arranz, and M J Otero, and R Ramos, and J L Steegmann, and M L Lamana, and J F Tomás, and R de la Cámara, and A Figuera, and L Vázquez, and J M Fernádez-Rañada
Severe acquired aplastic anemia in children: 11-year experience with bone marrow transplantation and immunosuppressive therapy.
January 1989, The American journal of pediatric hematology/oncology,
Copied contents to your clipboard!